{ "generatedAt": "2026-09-22", "offline": true, "requests": 0, "roadmaps": [ { "id": "adc-generations", "name": "ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 5, "checked": 5, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bl-b01d1-307", "name": "BL-B01D1-307", "nct": "NCT06382142", "corpus": { "status": "positive", "phase": "3", "enrolled": 418, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06382142", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 418, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-13", "completion": "2027-12", "lastUpdate": "2026-07-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast03", "name": "DESTINY-Breast03", "nct": "NCT03529110", "corpus": { "status": "positive", "phase": "3", "enrolled": 524, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03529110", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 524, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-05-21", "completion": "2026-07-30", "lastUpdate": "2025-10-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast04", "name": "DESTINY-Breast04", "nct": "NCT03734029", "corpus": { "status": "positive", "phase": "3", "enrolled": 557, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03734029", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 557, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-11", "completion": "2026-08-01", "lastUpdate": "2025-10-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ev-302", "name": "EV-302 / KEYNOTE-A39", "nct": "NCT04223856", "corpus": { "status": "positive", "phase": "3", "enrolled": 886, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04223856", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 886, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-08", "completion": "2028-03-01", "lastUpdate": "2026-05-29" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "ai-oncology-roadmap", "name": "AI in oncology roadmap: pattern readers → foundation models → agents in the workflow", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 1, "checked": 1, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "nct": "NCT04838756", "corpus": { "status": "positive", "phase": "3", "enrolled": 105934, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022.", "yearReported": 2023 }, "registry": { "nct": "NCT04838756", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 100000, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-07", "completion": "2025-08-12", "lastUpdate": "2026-04-02" }, "contradictions": [], "explained": [ "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." ], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "text": "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." } ] }, { "id": "ai-oncology-clinic", "name": "AI in the oncology clinic: from narrow cleared tools to multimodal decision support", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "prevention-roadmap", "name": "Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 8, "checked": 5, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "add-aspirin", "name": "Add-Aspirin", "nct": "NCT02804815", "corpus": { "status": "active", "phase": "3", "enrolled": 11000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02804815", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-10", "completion": "2026-10", "lastUpdate": "2025-06-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "alascca", "name": "ALASCCA", "nct": "NCT02647099", "corpus": { "status": "positive", "phase": "3", "enrolled": 626, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT02647099", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 626, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-08", "completion": "2026-08", "lastUpdate": "2026-03-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aspree", "name": "ASPREE (ASPirin in Reducing Events in the Elderly)", "nct": "NCT01038583", "corpus": { "status": "negative", "phase": "3", "enrolled": 19114, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01038583", "status": "UNKNOWN", "studyType": "OBSERVATIONAL", "enrolment": 19114, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-12", "completion": "2024-04", "lastUpdate": "2021-04-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "iarc-india-hpv-dose-study", "name": "IARC India HPV vaccine dose study (one, two or three doses)", "corpus": { "status": "positive", "phase": "observational", "enrolled": 17729, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "ken-she", "name": "KEN SHE (single-dose HPV vaccine)", "nct": "NCT03675256", "corpus": { "status": "positive", "phase": "4", "enrolled": 2275, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03675256", "status": "UNKNOWN", "phases": [ "PHASE4" ], "studyType": "INTERVENTIONAL", "enrolment": 2275, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-15", "completion": "2024-02-15", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nlst-nelson", "name": "NLST & NELSON (low-dose CT screening)", "corpus": { "status": "positive", "phase": "3", "enrolled": 53454, "enrolledBasis": "registry", "yearReported": 2011 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "nct": "NCT00883792", "corpus": { "status": "mixed", "phase": "3", "enrolled": 84585, "enrolledBasis": "analysed", "enrolledNote": "ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care).", "yearReported": 2022 }, "registry": { "nct": "NCT00883792", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 95000, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2036-07", "lastUpdate": "2017-06-19" }, "contradictions": [], "explained": [ "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." ], "papers": [] }, { "id": "osmanabad-hpv-screening", "name": "Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)", "corpus": { "status": "positive", "phase": "3", "enrolled": 131746, "enrolledBasis": "registry", "yearReported": 2009 }, "registry": null, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "nordicc", "name": "NordICC (Nordic-European Initiative on Colorectal Cancer)", "text": "enrolment 84585 in the corpus (analysed), 95000 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 95,000 participants (actual); the NEJM 2022 analysis covers the 84,585 participants in Poland, Norway and Sweden with follow-up data (28,220 invited, 56,365 usual care)." } ] }, { "id": "cell-therapy-roadmap", "name": "Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "chemotherapy-roadmap", "name": "Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 21, "checked": 15, "contradictions": 0, "explained": 2, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "apt-trial", "name": "APT (adjuvant paclitaxel-trastuzumab)", "nct": "NCT00542451", "corpus": { "status": "positive", "phase": "2", "enrolled": 406, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00542451", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 406, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-04-21", "completion": "2022-08-30", "lastUpdate": "2024-06-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-649", "name": "CheckMate 649", "nct": "NCT02872116", "corpus": { "status": "positive", "phase": "3", "enrolled": 1581, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm.", "yearReported": 2020 }, "registry": { "nct": "NCT02872116", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2031, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-05-27", "completion": "2024-06-06", "lastUpdate": "2025-08-07" }, "contradictions": [], "explained": [ "enrolment 1581 in the corpus (randomised), 2031 on the registry (actual; 22 percent apart): ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm." ], "papers": [] }, { "id": "cross", "name": "CROSS", "nct": "NTR487", "corpus": { "status": "positive", "phase": "3", "enrolled": 366, "enrolledBasis": "registry", "yearReported": 2012 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast06", "name": "DESTINY-Breast06", "nct": "NCT04494425", "corpus": { "status": "positive", "phase": "3", "enrolled": 866, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04494425", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 866, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-18", "completion": "2026-06-19", "lastUpdate": "2026-03-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "echelon-1", "name": "ECHELON-1", "nct": "NCT01712490", "corpus": { "status": "positive", "phase": "3", "enrolled": 1334, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01712490", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1334, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-04-20", "completion": "2026-02-02", "lastUpdate": "2026-02-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "eortc-26981", "name": "EORTC 26981 / NCIC CE.3 (Stupp trial)", "nct": "NCT00006353", "corpus": { "status": "positive", "phase": "3", "enrolled": 575, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00006353", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 575, "enrolmentType": "ACTUAL", "primaryCompletion": "2002-03", "lastUpdate": "2012-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ev-302", "name": "EV-302 / KEYNOTE-A39", "nct": "NCT04223856", "corpus": { "status": "positive", "phase": "3", "enrolled": 886, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04223856", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 886, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-08", "completion": "2028-03-01", "lastUpdate": "2026-05-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-024-189", "name": "KEYNOTE-024 & KEYNOTE-189", "nct": "NCT02142738", "corpus": { "status": "positive", "phase": "3", "enrolled": 921, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT02142738", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 305, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-05-09", "completion": "2021-05-27", "lastUpdate": "2022-06-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "low-dose-nivolumab-tmh", "name": "Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metro-plus-varanasi", "name": "METRO PLUS (Tata Memorial Centre, Varanasi)", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "napoli-3", "name": "NAPOLI 3", "nct": "NCT04083235", "corpus": { "status": "positive", "phase": "3", "enrolled": 770, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04083235", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 770, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-07-23", "completion": "2025-02-18", "lastUpdate": "2026-04-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "metronomic-vs-cisplatin-tmh", "name": "Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 422, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "polarix", "name": "POLARIX", "nct": "NCT03274492", "corpus": { "status": "positive", "phase": "3", "enrolled": 879, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP).", "yearReported": 2021 }, "registry": { "nct": "NCT03274492", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1000, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-04-30", "completion": "2026-04-30", "lastUpdate": "2026-05-08" }, "contradictions": [], "explained": [ "enrolment 879 in the corpus (randomised), 1000 on the registry (actual; 12 percent apart): ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP)." ], "papers": [] }, { "id": "prodige-24", "name": "PRODIGE 24 / CCTG PA6", "nct": "NCT01526135", "corpus": { "status": "positive", "phase": "3", "enrolled": 493, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01526135", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 493, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03", "completion": "2021-07-16", "lastUpdate": "2022-01-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rathl", "name": "RATHL", "nct": "NCT00678327", "corpus": { "status": "positive", "phase": "3", "enrolled": 1214, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00678327", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1202, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-01-31", "completion": "2024-05-01", "lastUpdate": "2024-05-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rxponder", "name": "RxPONDER (SWOG S1007)", "nct": "NCT01272037", "corpus": { "status": "positive", "phase": "3", "enrolled": 5018, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01272037", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5018, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-02-01", "completion": "2027-01-08", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "scarlet-s2212", "name": "SCARLET (SWOG S2212)", "nct": "NCT05929768", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 2400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05929768", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-03-31", "completion": "2033-04", "lastUpdate": "2025-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tailorx", "name": "TAILORx", "nct": "NCT00310180", "corpus": { "status": "positive", "phase": "3", "enrolled": 10273, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00310180", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 10273, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03-02", "completion": "2030-09-30", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "checkmate-649", "name": "CheckMate 649", "text": "enrolment 1581 in the corpus (randomised), 2031 on the registry (actual; 22 percent apart): ClinicalTrials.gov lists 2,031 participants (actual) across all three arms; the Lancet 2021 primary analysis concurrently randomised 1,581 patients to nivolumab plus chemotherapy or chemotherapy alone, leaving out the nivolumab plus ipilimumab arm." }, { "ref": "polarix", "name": "POLARIX", "text": "enrolment 879 in the corpus (randomised), 1000 on the registry (actual; 12 percent apart): ClinicalTrials.gov lists 1,000 participants (actual); the NEJM 2022 primary analysis randomised 879 patients (440 Pola-R-CHP, 439 R-CHOP)." } ] }, { "id": "ctdna-tests", "name": "ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment", "asOf": "2026-09-21", "since": "2026-09-21", "counts": { "trials": 12, "checked": 9, "contradictions": 0, "explained": 0, "papers": 0, "watch": 10, "watchPassed": 1 }, "trials": [ { "id": "bespoke-crc", "name": "BESPOKE CRC", "nct": "NCT04264702", "corpus": { "status": "active", "phase": "observational", "enrolled": 1788, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04264702", "status": "UNKNOWN", "studyType": "OBSERVATIONAL", "enrolment": 1788, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-09", "completion": "2025-09", "lastUpdate": "2023-12-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-us", "name": "CIRCULATE-US", "nct": "NCT05174169", "corpus": { "status": "recruiting", "phase": "2/3", "enrolled": 1912, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05174169", "status": "RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1912, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-03-10", "completion": "2030-03-10", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "eclipse-shield", "name": "ECLIPSE (Shield blood test)", "nct": "NCT04136002", "corpus": { "status": "positive", "phase": "observational", "enrolled": 44467, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04136002", "status": "ACTIVE_NOT_RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 44467, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-20", "completion": "2027-08-05", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-03-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mermaid-1", "name": "MERMAID-1", "nct": "NCT04385368", "corpus": { "status": "completed", "phase": "3", "enrolled": 89, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04385368", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 89, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-31", "completion": "2023-08-31", "lastUpdate": "2024-08-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mermaid-2", "name": "MERMAID-2", "nct": "NCT04642469", "corpus": { "status": "completed", "phase": "3", "enrolled": 30, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04642469", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 30, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-31", "completion": "2024-01-15", "lastUpdate": "2024-06-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nhs-galleri", "name": "NHS-Galleri", "nct": "ISRCTN91431511", "corpus": { "status": "completed", "phase": "3", "enrolled": 142000, "enrolledBasis": "registry" }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "pathfinder-2", "name": "PATHFINDER 2", "nct": "NCT05155605", "corpus": { "status": "active", "phase": "observational", "enrolled": 35883, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05155605", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 35883, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02-11", "completion": "2028-04-30", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tracc", "name": "TRACC", "nct": "NCT04050345", "corpus": { "status": "recruiting", "phase": "observational", "enrolled": 1000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04050345", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 1000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-07-31", "completion": "2031-07-31", "lastUpdate": "2024-06-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "vanguard-study", "name": "Vanguard Study (NCI Cancer Screening Research Network)", "nct": "NCT06995898", "corpus": { "status": "recruiting", "phase": "platform", "enrolled": 24000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06995898", "status": "RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 24000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-01-31", "completion": "2029-06-30", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [ { "item": "FDA Molecular and Clinical Genetics Panel reviews the Galleri premarket approval application", "expected": "2026-09-23", "source": "https://grail.com/press-releases/grail-announces-fda-advisory-committee-meeting-to-review-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test/", "refs": [ "galleri", "grail", "mced" ], "passed": false, "contradictions": [] }, { "item": "IMvigor011 study completion on the registry; longer follow-up of ctDNA-negative patients under surveillance", "expected": "2026-10-01", "source": "https://clinicaltrials.gov/study/NCT04660344", "refs": [ "imvigor011", "atezolizumab" ], "passed": false, "contradictions": [] }, { "item": "NHS-Galleri: peer-reviewed publication and continued follow-up; the release gives no mortality data", "source": "https://grail.com/press-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting/", "refs": [ "nhs-galleri", "galleri", "stage-shift" ], "passed": false, "contradictions": [] }, { "item": "ECLIPSE (Shield) study completion on the registry", "expected": "2027-08-05", "source": "https://clinicaltrials.gov/study/NCT04136002", "refs": [ "eclipse-shield", "shield" ], "passed": false, "contradictions": [] }, { "item": "PATHFINDER 2 study completion (primary completion listed as 2026-02-11)", "expected": "2028-04-30", "source": "https://clinicaltrials.gov/study/NCT05155605", "refs": [ "pathfinder-2", "galleri" ], "passed": false, "contradictions": [] }, { "item": "Vanguard study primary completion: the NCI's randomised feasibility trial of multi-cancer detection tests in 24,000 people", "expected": "2029-01-31", "source": "https://clinicaltrials.gov/study/NCT06995898", "refs": [ "vanguard-study", "nci" ], "passed": false, "contradictions": [] }, { "item": "CIRCULATE-US primary completion: ctDNA-guided escalation and de-escalation of adjuvant chemotherapy in stage III colon cancer", "expected": "2029-03-10", "source": "https://clinicaltrials.gov/study/NCT05174169", "refs": [ "circulate-us", "signatera" ], "passed": false, "contradictions": [] }, { "item": "TRACC primary completion: 1,000 people with early colorectal cancer followed by ctDNA", "expected": "2029-07-31", "source": "https://clinicaltrials.gov/study/NCT04050345", "refs": [ "tracc" ], "passed": false, "contradictions": [] }, { "item": "VEGA (CIRCULATE-Japan): non-inferiority of no chemotherapy in ctDNA-negative colon cancer; no readout date in the sources read", "source": "https://europepmc.org/article/MED/33931919", "refs": [ "circulate-japan" ], "passed": false, "contradictions": [] }, { "item": "BESPOKE CRC: registry status not updated since a listed completion of September 2025; watch for the primary publication", "expected": "2025-09", "source": "https://clinicaltrials.gov/study/NCT04264702", "refs": [ "bespoke-crc", "signatera" ], "passed": true, "contradictions": [] } ], "contradictions": [], "explained": [] }, { "id": "devices-roadmap", "name": "Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 4, "checked": 4, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ef-14", "name": "EF-14", "nct": "NCT00916409", "corpus": { "status": "positive", "phase": "3", "enrolled": 695, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00916409", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 700, "enrolmentType": "ESTIMATED", "primaryCompletion": "2016-12", "completion": "2017-03", "lastUpdate": "2017-04-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "panova-3", "name": "PANOVA-3", "nct": "NCT03377491", "corpus": { "status": "positive", "phase": "3", "enrolled": 571, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT03377491", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 571, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-16", "completion": "2024-10-16", "lastUpdate": "2026-01-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stellar", "name": "STELLAR", "nct": "NCT02397928", "corpus": { "status": "positive", "phase": "2", "enrolled": 82, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02397928", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 82, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-04", "completion": "2018-04", "lastUpdate": "2018-09-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "sunrise-1", "name": "SunRISe-1", "nct": "NCT04640623", "corpus": { "status": "positive", "phase": "2", "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04640623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 220, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-03", "completion": "2027-09-30", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "diagnostics-roadmap", "name": "Diagnostics roadmap: stains → gene panels → blood tests that decide treatment", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 8, "checked": 6, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-03-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "insight-gist", "name": "INSIGHT", "nct": "NCT05734105", "corpus": { "status": "active", "phase": "3", "enrolled": 54, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05734105", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 54, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-12", "lastUpdate": "2025-12-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "nct": "NCT04838756", "corpus": { "status": "positive", "phase": "3", "enrolled": 105934, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022.", "yearReported": 2023 }, "registry": { "nct": "NCT04838756", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 100000, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-07", "completion": "2025-08-12", "lastUpdate": "2026-04-02" }, "contradictions": [], "explained": [ "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." ], "papers": [] }, { "id": "rxponder", "name": "RxPONDER (SWOG S1007)", "nct": "NCT01272037", "corpus": { "status": "positive", "phase": "3", "enrolled": 5018, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01272037", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5018, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-02-01", "completion": "2027-01-08", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tailorx", "name": "TAILORx", "nct": "NCT00310180", "corpus": { "status": "positive", "phase": "3", "enrolled": 10273, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00310180", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 10273, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-03-02", "completion": "2030-09-30", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "masai", "name": "MASAI (Mammography Screening with Artificial Intelligence)", "text": "enrolment 105934 in the corpus (randomised), 100000 on the registry (actual; 6 percent apart): ClinicalTrials.gov lists 100,000 participants (actual); the Lancet 2026 interval-cancer analysis reports 105,934 women randomly assigned between April 2021 and December 2022." } ] }, { "id": "nutrition-lifestyle-roadmap", "name": "Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 10, "checked": 8, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "bwel", "name": "BWEL (Breast Cancer Weight Loss, Alliance A011401)", "nct": "NCT02750826", "corpus": { "status": "mixed", "phase": "3", "enrolled": 3181, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT02750826", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3177, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-05-30", "completion": "2030-05-30", "lastUpdate": "2026-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ergo2", "name": "ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma", "nct": "NCT01754350", "corpus": { "status": "negative", "phase": "2", "enrolled": 50, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01754350", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 50, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-12", "completion": "2019-03", "lastUpdate": "2021-06-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "fmt-pd1-refractory-melanoma-pitt", "name": "FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)", "nct": "NCT03341143", "corpus": { "status": "completed", "phase": "2", "enrolled": 15, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab.", "yearReported": 2021 }, "registry": { "nct": "NCT03341143", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 20, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-30", "completion": "2024-09-30", "lastUpdate": "2024-10-30" }, "contradictions": [], "explained": [ "enrolment 15 in the corpus (treated), 20 on the registry (actual; 25 percent apart): ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab." ], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "mimic-01", "name": "MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma", "nct": "NCT03772899", "corpus": { "status": "active", "phase": "1", "enrolled": 20, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03772899", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1" ], "studyType": "INTERVENTIONAL", "enrolment": 20, "enrolmentType": "ESTIMATED", "primaryCompletion": "2021-09-14", "completion": "2026-08", "lastUpdate": "2025-03-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ponsegromab-phase-2", "name": "Ponsegromab phase 2 in cancer cachexia", "nct": "NCT05546476", "corpus": { "status": "positive", "phase": "2", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05546476", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-13", "completion": "2025-04-23", "lastUpdate": "2026-06-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "vital", "name": "VITAL (VITamin D and OmegA-3 TriaL)", "nct": "NCT01169259", "corpus": { "status": "negative", "phase": "3", "enrolled": 25871, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT01169259", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 25871, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-11-10", "completion": "2026-10", "lastUpdate": "2026-07-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "whel", "name": "WHEL (Women's Healthy Eating and Living)", "nct": "NCT00003787", "corpus": { "status": "negative", "phase": "3", "enrolled": 3088, "enrolledBasis": "registry", "yearReported": 2007 }, "registry": { "nct": "NCT00003787", "status": "COMPLETED", "studyType": "OBSERVATIONAL", "enrolment": 3088, "enrolmentType": "ACTUAL", "primaryCompletion": "2007-03", "completion": "2018-12-31", "lastUpdate": "2019-06-10" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "fmt-pd1-refractory-melanoma-pitt", "name": "FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)", "text": "enrolment 15 in the corpus (treated), 20 on the registry (actual; 25 percent apart): ClinicalTrials.gov lists 20 participants (actual); the Science 2021 paper reports outcomes for the 15 patients who received FMT plus pembrolizumab." } ] }, { "id": "drug-discovery-roadmap", "name": "Drug discovery roadmap: screening in mice → maps of dependency → designing in silico", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "early-detection-roadmap", "name": "Early detection roadmap: organ screening → blood tests for many cancers", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 2, "checked": 1, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "nhs-galleri", "name": "NHS-Galleri", "nct": "ISRCTN91431511", "corpus": { "status": "completed", "phase": "3", "enrolled": 142000, "enrolledBasis": "registry" }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "pathfinder-2", "name": "PATHFINDER 2", "nct": "NCT05155605", "corpus": { "status": "active", "phase": "observational", "enrolled": 35883, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05155605", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 35883, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02-11", "completion": "2028-04-30", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "epigenetics-roadmap", "name": "Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 7, "checked": 7, "contradictions": 0, "explained": 2, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "agile", "name": "AGILE", "nct": "NCT03173248", "corpus": { "status": "positive", "phase": "3", "enrolled": 146, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03173248", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 146, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-03-18", "completion": "2026-06-30", "lastUpdate": "2026-06-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "augment-101", "name": "AUGMENT-101", "nct": "NCT04065399", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 94, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable).", "yearReported": 2024 }, "registry": { "nct": "NCT04065399", "status": "RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 447, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12-15", "completion": "2027-12-15", "lastUpdate": "2026-09-16" }, "contradictions": [], "explained": [ "enrolment 94 in the corpus (treated), 447 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable)." ], "papers": [] }, { "id": "claridhy", "name": "ClarIDHy", "nct": "NCT02989857", "corpus": { "status": "positive", "phase": "3", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02989857", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-01-31", "completion": "2021-05-17", "lastUpdate": "2024-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "golseek-1", "name": "GOLSEEK-1", "nct": "NCT06356129", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT06356129", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 850, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-08-09", "completion": "2029-06-26", "lastUpdate": "2026-07-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "komet-001", "name": "KOMET-001", "nct": "NCT04067336", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 112, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024.", "yearReported": 2025 }, "registry": { "nct": "NCT04067336", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 263, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-10-16", "completion": "2028-10-16", "lastUpdate": "2026-05-13" }, "contradictions": [], "explained": [ "enrolment 112 in the corpus (treated), 263 on the registry (estimated; 57 percent apart): ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024." ], "papers": [] }, { "id": "mevpro-1", "name": "MEVPRO-1", "nct": "NCT06551324", "corpus": { "status": "active", "phase": "3", "enrolled": 600, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06551324", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12-28", "completion": "2028-10-29", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "viale-a", "name": "VIALE-A", "nct": "NCT02993523", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02993523", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-12-01", "completion": "2026-06-15", "lastUpdate": "2026-06-11" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "augment-101", "name": "AUGMENT-101", "text": "enrolment 94 in the corpus (treated), 447 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 447 participants for the whole phase 1/2 programme, which is still recruiting; the JCO 2024 KMT2A-rearranged analysis treated 94 patients between October 2021 and July 2023 (57 efficacy-evaluable)." }, { "ref": "komet-001", "name": "KOMET-001", "text": "enrolment 112 in the corpus (treated), 263 on the registry (estimated; 57 percent apart): ClinicalTrials.gov lists an estimated 263 participants for the phase 1/2 study; 112 is the FDA efficacy population at 600 mg quoted in the approval coverage, while the JCO 2025 phase 2 paper reports 92 patients treated between January 2023 and May 2024." } ] }, { "id": "global-access-roadmap", "name": "Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 17, "checked": 6, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "nct": "NCT00193765", "corpus": { "status": "positive", "phase": "3", "enrolled": 596, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed.", "yearReported": 2015 }, "registry": { "nct": "NCT00193765", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 710, "enrolmentType": "ESTIMATED", "primaryCompletion": "2019-06", "completion": "2019-06", "lastUpdate": "2017-06-16" }, "contradictions": [], "explained": [ "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." ], "papers": [] }, { "id": "harmoni-2", "name": "HARMONi-2", "nct": "NCT05499390", "corpus": { "status": "positive", "phase": "3", "enrolled": 398, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05499390", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 398, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-29", "completion": "2026-12-31", "lastUpdate": "2026-03-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "iarc-india-hpv-dose-study", "name": "IARC India HPV vaccine dose study (one, two or three doses)", "corpus": { "status": "positive", "phase": "observational", "enrolled": 17729, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imagine-varnimcabtagene", "name": "IMAGINE (varnimcabtagene autoleucel, Immuneel)", "corpus": { "status": "positive", "phase": "2", "enrolled": 24, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ken-she", "name": "KEN SHE (single-dose HPV vaccine)", "nct": "NCT03675256", "corpus": { "status": "positive", "phase": "4", "enrolled": 2275, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03675256", "status": "UNKNOWN", "phases": [ "PHASE4" ], "studyType": "INTERVENTIONAL", "enrolment": 2275, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-15", "completion": "2024-02-15", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "kerala-oral-screening", "name": "Kerala oral cancer visual screening trial (Trivandrum)", "corpus": { "status": "positive", "phase": "3", "enrolled": 191873, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "low-dose-nivolumab-tmh", "name": "Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metro-plus-varanasi", "name": "METRO PLUS (Tata Memorial Centre, Varanasi)", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "mumbai-via-screening", "name": "Mumbai VIA cervical screening trial (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 151538, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "metronomic-vs-cisplatin-tmh", "name": "Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 422, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "orient-11", "name": "ORIENT-11", "nct": "NCT03607539", "corpus": { "status": "positive", "phase": "3", "enrolled": 397, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03607539", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 397, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-11-15", "completion": "2022-05-31", "lastUpdate": "2026-05-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "osmanabad-hpv-screening", "name": "Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)", "corpus": { "status": "positive", "phase": "3", "enrolled": 131746, "enrolledBasis": "registry", "yearReported": 2009 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "persephone", "name": "PERSEPHONE", "nct": "NCT00712140", "corpus": { "status": "positive", "phase": "3", "enrolled": 4088, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT00712140", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2011-10", "lastUpdate": "2011-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "reliance", "name": "RELIANCE", "corpus": { "status": "positive", "phase": "2", "enrolled": 59, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "progesterone-preop-tmh", "name": "Single-injection depot progesterone before breast surgery (Tata Memorial)", "corpus": { "status": "mixed", "phase": "3", "enrolled": 976, "enrolledBasis": "registry", "yearReported": 2011 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "talicel-phase-1-2", "name": "Talicabtagene autoleucel (NexCAR19) phase 1/2", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 64, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": null, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "text": "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." } ] }, { "id": "hormonal-therapy-roadmap", "name": "Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 32, "checked": 32, "contradictions": 0, "explained": 5, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "arasens", "name": "ARASENS", "nct": "NCT02799602", "corpus": { "status": "positive", "phase": "3", "enrolled": 1306, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT02799602", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1306, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-10-25", "completion": "2023-04-11", "lastUpdate": "2025-12-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "arches", "name": "ARCHES", "nct": "NCT02677896", "corpus": { "status": "positive", "phase": "3", "enrolled": 1150, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT02677896", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1150, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-10-14", "completion": "2024-07-31", "lastUpdate": "2025-10-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "cambria", "name": "CAMBRIA-1 & CAMBRIA-2", "nct": "NCT05952557", "corpus": { "status": "active", "phase": "3", "enrolled": 10000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05952557", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5511, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-03-04", "completion": "2037-05-06", "lastUpdate": "2026-08-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "capitello-281", "name": "CAPItello-281", "nct": "NCT04493853", "corpus": { "status": "positive", "phase": "3", "enrolled": 1012, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04493853", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1012, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-10-07", "completion": "2027-03-31", "lastUpdate": "2026-09-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "capitello-291", "name": "CAPItello-291", "nct": "NCT04305496", "corpus": { "status": "positive", "phase": "3", "enrolled": 708, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients.", "yearReported": 2022 }, "registry": { "nct": "NCT04305496", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 818, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-09", "completion": "2026-06-22", "lastUpdate": "2026-04-30" }, "contradictions": [], "explained": [ "enrolment 708 in the corpus (randomised), 818 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients." ], "papers": [] }, { "id": "chaarted", "name": "CHAARTED (E3805)", "nct": "NCT00309985", "corpus": { "status": "positive", "phase": "3", "enrolled": 790, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT00309985", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 790, "enrolmentType": "ACTUAL", "primaryCompletion": "2013-12-23", "completion": "2025-01-31", "lastUpdate": "2025-12-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "embark", "name": "EMBARK", "nct": "NCT02319837", "corpus": { "status": "positive", "phase": "3", "enrolled": 1068, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT02319837", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1068, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-01-31", "completion": "2026-09-19", "lastUpdate": "2026-07-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ember-3", "name": "EMBER-3", "nct": "NCT04975308", "corpus": { "status": "positive", "phase": "3", "enrolled": 874, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04975308", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 874, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-06-24", "completion": "2027-08", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "emerald", "name": "EMERALD", "nct": "NCT03778931", "corpus": { "status": "positive", "phase": "3", "enrolled": 478, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03778931", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 478, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-24", "completion": "2024-08-22", "lastUpdate": "2025-09-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "evera", "name": "evERA", "nct": "NCT05306340", "corpus": { "status": "positive", "phase": "3", "enrolled": 320, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication.", "yearReported": 2025 }, "registry": { "nct": "NCT05306340", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 373, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-16", "completion": "2026-10-15", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [ "enrolment 320 in the corpus (randomised), 373 on the registry (actual; 14 percent apart): ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication." ], "papers": [] }, { "id": "fourlight-1", "name": "FOURLIGHT-1", "nct": "NCT06105632", "corpus": { "status": "positive", "phase": "2", "enrolled": 333, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06105632", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 333, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-12", "completion": "2028-01-21", "lastUpdate": "2026-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "latitude", "name": "LATITUDE", "nct": "NCT01715285", "corpus": { "status": "positive", "phase": "3", "enrolled": 1209, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01715285", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1209, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-10-31", "completion": "2022-02-13", "lastUpdate": "2025-02-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "lidera", "name": "lidERA", "nct": "NCT04961996", "corpus": { "status": "positive", "phase": "3", "enrolled": 4170, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04961996", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4170, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-08", "completion": "2033-09-30", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "magnitude", "name": "MAGNITUDE", "nct": "NCT03748641", "corpus": { "status": "mixed", "phase": "3", "enrolled": 423, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort.", "yearReported": 2022 }, "registry": { "nct": "NCT03748641", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 765, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-10-08", "completion": "2027-12-31", "lastUpdate": "2026-09-21" }, "contradictions": [], "explained": [ "enrolment 423 in the corpus (randomised), 765 on the registry (actual; 45 percent apart): ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort." ], "papers": [] }, { "id": "mevpro-1", "name": "MEVPRO-1", "nct": "NCT06551324", "corpus": { "status": "active", "phase": "3", "enrolled": 600, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06551324", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12-28", "completion": "2028-10-29", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monaleesa-2", "name": "MONALEESA-2", "nct": "NCT01958021", "corpus": { "status": "positive", "phase": "3", "enrolled": 668, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01958021", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 668, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-01-29", "completion": "2023-03-16", "lastUpdate": "2025-03-07" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monarch-3", "name": "MONARCH 3", "nct": "NCT02246621", "corpus": { "status": "positive", "phase": "3", "enrolled": 493, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02246621", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 493, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-01-31", "completion": "2026-12", "lastUpdate": "2026-02-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "monarche", "name": "monarchE", "nct": "NCT03155997", "corpus": { "status": "positive", "phase": "3", "enrolled": 5637, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03155997", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5637, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-16", "completion": "2029-05", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "natalee", "name": "NATALEE", "nct": "NCT03701334", "corpus": { "status": "positive", "phase": "3", "enrolled": 5101, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03701334", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5101, "enrolmentType": "ACTUAL", "primaryCompletion": "2030-05-29", "completion": "2030-05-29", "lastUpdate": "2026-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pallas-penelope-b", "name": "PALLAS & PENELOPE-B", "nct": "NCT02513394", "corpus": { "status": "negative", "phase": "3", "enrolled": 6862, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02513394", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5796, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-11", "completion": "2028-12", "lastUpdate": "2026-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "paloma-2", "name": "PALOMA-2", "nct": "NCT01740427", "corpus": { "status": "mixed", "phase": "3", "enrolled": 666, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01740427", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 666, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-02-26", "completion": "2023-11-09", "lastUpdate": "2024-11-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "peace-1", "name": "PEACE-1", "nct": "NCT01957436", "corpus": { "status": "positive", "phase": "3", "enrolled": 1173, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT01957436", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1173, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-18", "completion": "2032-12", "lastUpdate": "2024-11-12" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "persevera", "name": "persevERA", "nct": "NCT04546009", "corpus": { "status": "negative", "phase": "3", "enrolled": 992, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT04546009", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-30", "completion": "2027-07-31", "lastUpdate": "2026-08-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "postmonarch", "name": "postMONARCH", "nct": "NCT05169567", "corpus": { "status": "positive", "phase": "3", "enrolled": 368, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05169567", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 368, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-02-08", "completion": "2027-12", "lastUpdate": "2026-01-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "propel", "name": "PROpel", "nct": "NCT03732820", "corpus": { "status": "positive", "phase": "3", "enrolled": 796, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03732820", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 895, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-07-30", "completion": "2027-02-05", "lastUpdate": "2026-08-18" }, "contradictions": [], "explained": [ "enrolment 796 in the corpus (randomised), 895 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis." ], "papers": [] }, { "id": "psmafore", "name": "PSMAfore", "nct": "NCT04689828", "corpus": { "status": "positive", "phase": "3", "enrolled": 469, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04689828", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 469, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-02", "completion": "2026-09-10", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "soft-text", "name": "SOFT & TEXT", "nct": "NCT00066690", "corpus": { "status": "positive", "phase": "3", "enrolled": 5738, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": { "nct": "NCT00066690", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3066, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-05", "completion": "2024-11-06", "lastUpdate": "2026-08-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "solar-1", "name": "SOLAR-1", "nct": "NCT02437318", "corpus": { "status": "positive", "phase": "3", "enrolled": 572, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02437318", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 572, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-06-12", "completion": "2023-06-09", "lastUpdate": "2025-02-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stampede", "name": "STAMPEDE", "nct": "NCT00268476", "corpus": { "status": "positive", "phase": "platform", "enrolled": 11992, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00268476", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03", "completion": "2030-12", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "talapro-2", "name": "TALAPRO-2", "nct": "NCT03395197", "corpus": { "status": "positive", "phase": "3", "enrolled": 805, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo).", "yearReported": 2023 }, "registry": { "nct": "NCT03395197", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1054, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-03", "completion": "2027-06-30", "lastUpdate": "2026-09-08" }, "contradictions": [], "explained": [ "enrolment 805 in the corpus (randomised), 1054 on the registry (actual; 24 percent apart): ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo)." ], "papers": [] }, { "id": "veritac-2", "name": "VERITAC-2", "nct": "NCT05654623", "corpus": { "status": "mixed", "phase": "3", "enrolled": 624, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05654623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 624, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-31", "completion": "2028-05-15", "lastUpdate": "2026-03-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "capitello-291", "name": "CAPItello-291", "text": "enrolment 708 in the corpus (randomised), 818 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 818 participants (actual); the NEJM 2023 primary analysis randomised 708 patients." }, { "ref": "evera", "name": "evERA", "text": "enrolment 320 in the corpus (randomised), 373 on the registry (actual; 14 percent apart): ClinicalTrials.gov lists 373 participants (actual); 320 is the randomised population presented at ESMO 2025 and quoted in the summary. No journal paper is indexed on Europe PMC yet, so the figure has not been checked against a primary publication." }, { "ref": "magnitude", "name": "MAGNITUDE", "text": "enrolment 423 in the corpus (randomised), 765 on the registry (actual; 45 percent apart): ClinicalTrials.gov lists 765 participants (actual) across all cohorts; the JCO 2023 primary analysis randomised 423 patients in the HRR-positive cohort, the population behind the headline result, and 247 in the HRR-negative cohort." }, { "ref": "propel", "name": "PROpel", "text": "enrolment 796 in the corpus (randomised), 895 on the registry (actual; 11 percent apart): ClinicalTrials.gov lists 895 participants (actual); 1,103 patients were screened and 796 randomised (399 olaparib, 397 placebo) in the primary analysis." }, { "ref": "talapro-2", "name": "TALAPRO-2", "text": "enrolment 805 in the corpus (randomised), 1054 on the registry (actual; 24 percent apart): ClinicalTrials.gov lists 1,054 participants (actual) across both cohorts; the Lancet 2023 primary analysis randomised 805 patients in the all-comers cohort (402 talazoparib, 403 placebo)." } ] }, { "id": "immunotherapy-roadmap", "name": "Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 4, "checked": 4, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-067", "name": "CheckMate 067", "nct": "NCT01844505", "corpus": { "status": "positive", "phase": "3", "enrolled": 945, "enrolledBasis": "registry", "yearReported": 2015 }, "registry": { "nct": "NCT01844505", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 945, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-08-01", "completion": "2024-04-19", "lastUpdate": "2025-05-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interpath-001", "name": "INTerpath-001 (V940-001)", "nct": "NCT05933577", "corpus": { "status": "positive", "phase": "3", "enrolled": 1137, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05933577", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1089, "enrolmentType": "ESTIMATED", "primaryCompletion": "2029-10-26", "completion": "2030-09-26", "lastUpdate": "2025-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "kras-roadmap", "name": "KRAS roadmap: undruggable → G12C → pan-RAS", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "molecular-imaging-roadmap", "name": "Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "paediatric-oncology-roadmap", "name": "Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 20, "checked": 20, "contradictions": 0, "explained": 6, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "action-dmg", "name": "ACTION", "nct": "NCT05580562", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 510, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05580562", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 510, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-06", "completion": "2028-06", "lastUpdate": "2026-04-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ccss", "name": "Childhood Cancer Survivor Study (CCSS)", "nct": "NCT01120353", "corpus": { "status": "active", "phase": "observational", "enrolled": 50000, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01120353", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 50000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-11", "completion": "2026-11", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aall1731", "name": "COG AALL1731", "nct": "NCT03914625", "corpus": { "status": "positive", "phase": "3", "enrolled": 1440, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped.", "yearReported": 2024 }, "registry": { "nct": "NCT03914625", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 6720, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-09-30", "completion": "2027-09-30", "lastUpdate": "2026-07-30" }, "contradictions": [], "explained": [ "enrolment 1440 in the corpus (randomised), 6720 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped." ], "papers": [] }, { "id": "aaml0531", "name": "COG AAML0531", "nct": "NCT00372593", "corpus": { "status": "positive", "phase": "3", "enrolled": 1070, "enrolledBasis": "registry", "yearReported": 2014 }, "registry": { "nct": "NCT00372593", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1070, "enrolmentType": "ACTUAL", "primaryCompletion": "2013-08", "completion": "2020-09-30", "lastUpdate": "2021-03-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "acns0331", "name": "COG ACNS0331", "nct": "NCT00085735", "corpus": { "status": "mixed", "phase": "3", "enrolled": 549, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT00085735", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 549, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-03-31", "completion": "2024-12-31", "lastUpdate": "2026-06-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "anbl0032", "name": "COG ANBL0032", "nct": "NCT00026312", "corpus": { "status": "positive", "phase": "3", "enrolled": 226, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients.", "yearReported": 2010 }, "registry": { "nct": "NCT00026312", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1449, "enrolmentType": "ACTUAL", "primaryCompletion": "2012-01-12", "completion": "2025-12-31", "lastUpdate": "2026-03-05" }, "contradictions": [], "explained": [ "enrolment 226 in the corpus (randomised), 1449 on the registry (actual; 84 percent apart): ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients." ], "papers": [] }, { "id": "anbl0532", "name": "COG ANBL0532", "nct": "NCT00567567", "corpus": { "status": "positive", "phase": "3", "enrolled": 665, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00567567", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 665, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-02-27", "completion": "2022-03-31", "lastUpdate": "2022-04-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "anbl1531", "name": "COG ANBL1531", "nct": "NCT03126916", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT03126916", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 750, "enrolmentType": "ESTIMATED", "primaryCompletion": "2030-09-30", "completion": "2030-09-30", "lastUpdate": "2026-08-25" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "aren0533", "name": "COG AREN0533", "nct": "NCT00379340", "corpus": { "status": "positive", "phase": "3", "enrolled": 395, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00379340", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 395, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-06-30", "completion": "2026-03-31", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "eliana", "name": "ELIANA", "nct": "NCT02435849", "corpus": { "status": "positive", "phase": "2", "enrolled": 79, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists 80 participants (actual); the JCO 2023 three-year update reports 79 infused patients and the NEJM 2018 primary analysis 75.", "yearReported": 2018 }, "registry": { "nct": "NCT02435849", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 80, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-01-21", "completion": "2022-11-17", "lastUpdate": "2024-02-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "euramos-1", "name": "EURAMOS-1", "nct": "NCT00134030", "corpus": { "status": "negative", "phase": "3", "enrolled": 2260, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries.", "yearReported": 2016 }, "registry": { "nct": "NCT00134030", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1334, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-01-31", "completion": "2022-09-30", "lastUpdate": "2023-06-07" }, "contradictions": [], "explained": [ "enrolment 2260 in the corpus (registered), 1334 on the registry (actual; 69 percent apart): ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries." ], "papers": [] }, { "id": "firefly-1", "name": "FIREFLY-1", "nct": "NCT04775485", "corpus": { "status": "positive", "phase": "2", "enrolled": 141, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04775485", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 141, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-05-31", "completion": "2027-05-31", "lastUpdate": "2025-04-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "gd2-cart01", "name": "GD2-CART01 (Bambino Gesù phase 1/2)", "nct": "NCT03373097", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 27, "enrolledBasis": "treated", "enrolledNote": "ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated.", "yearReported": 2023 }, "registry": { "nct": "NCT03373097", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 42, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-12", "completion": "2027-12", "lastUpdate": "2025-02-05" }, "contradictions": [], "explained": [ "enrolment 27 in the corpus (treated), 42 on the registry (estimated; 36 percent apart): ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated." ], "papers": [] }, { "id": "int-0091", "name": "INT-0091 (Ewing sarcoma)", "nct": "NCT00002516", "corpus": { "status": "positive", "phase": "3", "enrolled": 518, "enrolledBasis": "registry", "yearReported": 2003 }, "registry": { "nct": "NCT00002516", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "lastUpdate": "2013-09-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "inter-b-nhl-ritux-2010", "name": "Inter-B-NHL Ritux 2010", "nct": "NCT01516580", "corpus": { "status": "positive", "phase": "3", "enrolled": 482, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT01516580", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 482, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-06-13", "completion": "2022-11-16", "lastUpdate": "2026-02-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interfant-06", "name": "Interfant-06", "nct": "NCT00550992", "corpus": { "status": "mixed", "phase": "3", "enrolled": 651, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included.", "yearReported": 2019 }, "registry": { "nct": "NCT00550992", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 445, "enrolmentType": "ESTIMATED", "primaryCompletion": "2020-12", "lastUpdate": "2019-07-30" }, "contradictions": [], "explained": [ "enrolment 651 in the corpus (registered), 445 on the registry (estimated; 46 percent apart): ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included." ], "papers": [] }, { "id": "pediatric-match", "name": "NCI-COG Pediatric MATCH (APEC1621)", "nct": "NCT03155620", "corpus": { "status": "active", "phase": "platform", "enrolled": 1377, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03155620", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 1377, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-31", "completion": "2027-01-06", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "hr-nbl1", "name": "SIOPEN HR-NBL1", "nct": "NCT01704716", "corpus": { "status": "mixed", "phase": "3", "enrolled": 3300, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01704716", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 3300, "enrolmentType": "ESTIMATED", "primaryCompletion": "2021-09-30", "completion": "2026-09", "lastUpdate": "2020-10-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tadpole", "name": "TADPOLE (CDRB436G2201)", "nct": "NCT02684058", "corpus": { "status": "positive", "phase": "2", "enrolled": 110, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy).", "yearReported": 2023 }, "registry": { "nct": "NCT02684058", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 151, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-08-23", "completion": "2023-04-28", "lastUpdate": "2023-12-13" }, "contradictions": [], "explained": [ "enrolment 110 in the corpus (randomised), 151 on the registry (actual; 27 percent apart): ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy)." ], "papers": [] }, { "id": "tower", "name": "TOWER", "nct": "NCT02013167", "corpus": { "status": "positive", "phase": "3", "enrolled": 405, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02013167", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 405, "enrolmentType": "ACTUAL", "primaryCompletion": "2015-12-29", "completion": "2017-03-14", "lastUpdate": "2024-03-05" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "aall1731", "name": "COG AALL1731", "text": "enrolment 1440 in the corpus (randomised), 6720 on the registry (estimated; 79 percent apart): ClinicalTrials.gov lists an estimated 6,720 participants for the whole trial, which enrols all standard-risk patients; the NEJM 2024 interim analysis covered the 1,440 patients randomised (722 chemotherapy, 718 blinatumomab) before randomisation was stopped." }, { "ref": "anbl0032", "name": "COG ANBL0032", "text": "enrolment 226 in the corpus (randomised), 1449 on the registry (actual; 84 percent apart): ClinicalTrials.gov lists 1,449 participants (actual) enrolled over the life of the study; the NEJM 2010 analysis randomised 226 eligible patients." }, { "ref": "euramos-1", "name": "EURAMOS-1", "text": "enrolment 2260 in the corpus (registered), 1334 on the registry (actual; 69 percent apart): ClinicalTrials.gov lists 1,334 participants (actual), the patients randomised (618 poor responders and 716 good responders); the Lancet Oncology 2016 paper reports 2,260 patients registered from 325 sites in 17 countries." }, { "ref": "gd2-cart01", "name": "GD2-CART01 (Bambino Gesù phase 1/2)", "text": "enrolment 27 in the corpus (treated), 42 on the registry (estimated; 36 percent apart): ClinicalTrials.gov lists an estimated 42 participants for the phase 1/2 study, which is still active; the NEJM 2023 paper reports the 27 patients treated." }, { "ref": "interfant-06", "name": "Interfant-06", "text": "enrolment 651 in the corpus (registered), 445 on the registry (estimated; 46 percent apart): ClinicalTrials.gov lists an estimated 445 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the JCO 2019 paper reports 651 infants included." }, { "ref": "tadpole", "name": "TADPOLE (CDRB436G2201)", "text": "enrolment 110 in the corpus (randomised), 151 on the registry (actual; 27 percent apart): ClinicalTrials.gov lists 151 participants (actual) across the study's cohorts; the NEJM 2023 low-grade glioma analysis randomised 110 patients (73 dabrafenib plus trametinib, 37 chemotherapy)." } ] }, { "id": "cure-paths", "name": "Paths to cures: interception, eradication, control", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "frontier-2035", "name": "Radical oncology: what could change the war by 2035", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] }, { "id": "radiopharma-roadmap", "name": "Radiopharmaceutical roadmap: iodine → lutetium → actinium", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 2, "checked": 2, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "psmafore", "name": "PSMAfore", "nct": "NCT04689828", "corpus": { "status": "positive", "phase": "3", "enrolled": 469, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04689828", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 469, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-10-02", "completion": "2026-09-10", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "vision", "name": "VISION", "nct": "NCT03511664", "corpus": { "status": "positive", "phase": "3", "enrolled": 861, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT03511664", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 861, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-01-27", "completion": "2023-12-14", "lastUpdate": "2025-01-13" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "radiation-roadmap", "name": "Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 13, "checked": 12, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "acns0331", "name": "COG ACNS0331", "nct": "NCT00085735", "corpus": { "status": "mixed", "phase": "3", "enrolled": 549, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT00085735", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 549, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-03-31", "completion": "2024-12-31", "lastUpdate": "2026-06-09" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "convert", "name": "CONVERT", "nct": "NCT00433563", "corpus": { "status": "mixed", "phase": "3", "enrolled": 547, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT00433563", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 547, "enrolmentType": "ACTUAL", "primaryCompletion": "2016-02", "completion": "2019-01", "lastUpdate": "2022-09-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "cross", "name": "CROSS", "nct": "NTR487", "corpus": { "status": "positive", "phase": "3", "enrolled": 366, "enrolledBasis": "registry", "yearReported": 2012 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "eortc-26981", "name": "EORTC 26981 / NCIC CE.3 (Stupp trial)", "nct": "NCT00006353", "corpus": { "status": "positive", "phase": "3", "enrolled": 575, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00006353", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 575, "enrolmentType": "ACTUAL", "primaryCompletion": "2002-03", "lastUpdate": "2012-09-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "estimabl2", "name": "ESTIMABL2", "nct": "NCT01837745", "corpus": { "status": "positive", "phase": "3", "enrolled": 776, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT01837745", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-01", "completion": "2030-01-01", "lastUpdate": "2023-05-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "interlace", "name": "INTERLACE", "nct": "NCT01566240", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT01566240", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-02", "completion": "2026-12", "lastUpdate": "2024-12-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "javelin-hn-100", "name": "JAVELIN Head and Neck 100", "nct": "NCT02952586", "corpus": { "status": "negative", "phase": "3", "enrolled": 697, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02952586", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 697, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-12-23", "completion": "2020-08-25", "lastUpdate": "2021-09-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-a18", "name": "KEYNOTE-A18 / ENGOT-cx11 / GOG-3047", "nct": "NCT04221945", "corpus": { "status": "positive", "phase": "3", "enrolled": 1060, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04221945", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1060, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-07", "completion": "2026-01-26", "lastUpdate": "2026-02-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "laura", "name": "LAURA", "nct": "NCT03521154", "corpus": { "status": "positive", "phase": "3", "enrolled": 216, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03521154", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 216, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-05", "completion": "2027-10-29", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nrg-hn002-hn005", "name": "NRG-HN002 & NRG-HN005 (HPV+ de-escalation)", "nct": "NCT03952585", "corpus": { "status": "mixed", "phase": "2/3", "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT03952585", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 384, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-01", "completion": "2026-12-11", "lastUpdate": "2026-07-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pacific", "name": "PACIFIC", "nct": "NCT02125461", "corpus": { "status": "positive", "phase": "3", "enrolled": 713, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT02125461", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 713, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-02-13", "completion": "2023-08-24", "lastUpdate": "2023-10-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "portec-3", "name": "PORTEC-3", "nct": "NCT00411138", "corpus": { "status": "positive", "phase": "3", "enrolled": 660, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00411138", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 670, "enrolmentType": "ESTIMATED", "primaryCompletion": "2018-11-29", "completion": "2024-12-31", "lastUpdate": "2023-10-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "trilynx", "name": "TrilynX", "nct": "NCT04459715", "corpus": { "status": "negative", "phase": "3", "enrolled": 730, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04459715", "status": "TERMINATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 730, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-09-18", "completion": "2024-09-18", "lastUpdate": "2025-10-08" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "survivorship-roadmap", "name": "Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 6, "checked": 4, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ccss", "name": "Childhood Cancer Survivor Study (CCSS)", "nct": "NCT01120353", "corpus": { "status": "active", "phase": "observational", "enrolled": 50000, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01120353", "status": "RECRUITING", "studyType": "OBSERVATIONAL", "enrolment": 50000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-11", "completion": "2026-11", "lastUpdate": "2026-06-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olanzapine-appetite-tmh", "name": "Low-dose olanzapine for cancer anorexia (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 124, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "ponsegromab-phase-2", "name": "Ponsegromab phase 2 in cancer cachexia", "nct": "NCT05546476", "corpus": { "status": "positive", "phase": "2", "enrolled": 187, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT05546476", "status": "COMPLETED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 187, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-03-13", "completion": "2025-04-23", "lastUpdate": "2026-06-03" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "romana-1-2", "name": "ROMANA 1 and ROMANA 2", "nct": "NCT01387269", "corpus": { "status": "mixed", "phase": "3", "enrolled": 979, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT01387269", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 484, "enrolmentType": "ACTUAL", "primaryCompletion": "2014-01", "completion": "2015-02", "lastUpdate": "2017-10-27" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [] }, { "id": "surgery-roadmap", "name": "Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 22, "checked": 20, "contradictions": 0, "explained": 5, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "azur-1", "name": "AZUR-1", "nct": "NCT05723562", "corpus": { "status": "positive", "phase": "2", "enrolled": 154, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT05723562", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 154, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-11-02", "completion": "2029-10-11", "lastUpdate": "2026-05-26" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "checkmate-816", "name": "CheckMate 816", "nct": "NCT02998528", "corpus": { "status": "positive", "phase": "3", "enrolled": 358, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy.", "yearReported": 2022 }, "registry": { "nct": "NCT02998528", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 505, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-09-08", "completion": "2024-12-06", "lastUpdate": "2026-01-06" }, "contradictions": [], "explained": [ "enrolment 358 in the corpus (randomised), 505 on the registry (actual; 29 percent apart): ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy." ], "papers": [] }, { "id": "destiny-breast11", "name": "DESTINY-Breast11", "nct": "NCT05113251", "corpus": { "status": "positive", "phase": "3", "enrolled": 927, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05113251", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 927, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-12", "completion": "2027-04-30", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "nct": "NCT00193765", "corpus": { "status": "positive", "phase": "3", "enrolled": 596, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed.", "yearReported": 2015 }, "registry": { "nct": "NCT00193765", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 710, "enrolmentType": "ESTIMATED", "primaryCompletion": "2019-06", "completion": "2019-06", "lastUpdate": "2017-06-16" }, "contradictions": [], "explained": [ "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." ], "papers": [] }, { "id": "emerald-1", "name": "EMERALD-1", "nct": "NCT03778957", "corpus": { "status": "mixed", "phase": "3", "enrolled": 616, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms).", "yearReported": 2024 }, "registry": { "nct": "NCT03778957", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 724, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-11", "completion": "2026-08-31", "lastUpdate": "2026-07-15" }, "contradictions": [], "explained": [ "enrolment 616 in the corpus (randomised), 724 on the registry (actual; 15 percent apart): ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms)." ], "papers": [] }, { "id": "estimabl2", "name": "ESTIMABL2", "nct": "NCT01837745", "corpus": { "status": "positive", "phase": "3", "enrolled": 776, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT01837745", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-01", "completion": "2030-01-01", "lastUpdate": "2023-05-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "fires-sentor", "name": "FIRES & SENTOR (sentinel node mapping)", "nct": "NCT01673022", "corpus": { "status": "positive", "phase": "observational", "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01673022", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 430, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-01", "completion": "2017-01", "lastUpdate": "2018-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-671", "name": "KEYNOTE-671", "nct": "NCT03425643", "corpus": { "status": "positive", "phase": "3", "enrolled": 797, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03425643", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 797, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-07-10", "completion": "2026-10-15", "lastUpdate": "2026-07-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "lacc", "name": "LACC (Laparoscopic Approach to Cervical Cancer)", "nct": "NCT00614211", "corpus": { "status": "negative", "phase": "3", "enrolled": 636, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00614211", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 636, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-03", "completion": "2022-03", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mars-2", "name": "MARS 2", "nct": "NCT02040272", "corpus": { "status": "negative", "phase": "3", "enrolled": 335, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT02040272", "status": "UNKNOWN", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 328, "enrolmentType": "ESTIMATED", "primaryCompletion": "2020-09", "completion": "2022-09", "lastUpdate": "2019-10-30" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "matterhorn", "name": "MATTERHORN", "nct": "NCT04592913", "corpus": { "status": "positive", "phase": "3", "enrolled": 957, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04592913", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 957, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-12-20", "completion": "2027-09-27", "lastUpdate": "2025-12-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mslt-ii", "name": "MSLT-II", "nct": "NCT00297895", "corpus": { "status": "positive", "phase": "3", "enrolled": 1939, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT00297895", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 1939, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-09-30", "completion": "2019-09-30", "lastUpdate": "2022-05-13" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "nadina", "name": "NADINA", "nct": "NCT04949113", "corpus": { "status": "positive", "phase": "3", "enrolled": 423, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04949113", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 423, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-12", "completion": "2028-12-19", "lastUpdate": "2024-03-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niagara", "name": "NIAGARA", "nct": "NCT03732677", "corpus": { "status": "positive", "phase": "3", "enrolled": 1063, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03732677", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1063, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-04-29", "completion": "2027-11-08", "lastUpdate": "2026-07-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niche-2", "name": "NICHE-2", "nct": "NCT03026140", "corpus": { "status": "positive", "phase": "2", "enrolled": 115, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03026140", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 353, "enrolmentType": "ESTIMATED", "primaryCompletion": "2032-03-01", "completion": "2032-03-01", "lastUpdate": "2026-03-05" }, "contradictions": [], "explained": [ "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." ], "papers": [] }, { "id": "ovhipec-1", "name": "OVHIPEC-1", "nct": "NCT00426257", "corpus": { "status": "positive", "phase": "3", "enrolled": 245, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT00426257", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 242, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-08-16", "completion": "2017-08-16", "lastUpdate": "2018-08-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "prehab-trial", "name": "PREHAB: multimodal prehabilitation before colorectal cancer surgery", "corpus": { "status": "positive", "phase": "3", "enrolled": 251, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "preopanc", "name": "PREOPANC-1 / PREOPANC-2", "nct": "NTR3709", "corpus": { "status": "mixed", "phase": "3", "enrolled": 246, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "sano", "name": "SANO", "nct": "NCT05953181", "corpus": { "status": "positive", "phase": "3", "enrolled": 309, "enrolledBasis": "analysed", "enrolledNote": "ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery).", "yearReported": 2023 }, "registry": { "nct": "NCT05953181", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 776, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-06-01", "completion": "2026-06-01", "lastUpdate": "2024-09-19" }, "contradictions": [], "explained": [ "enrolment 309 in the corpus (analysed), 776 on the registry (actual; 60 percent apart): ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery)." ], "papers": [] }, { "id": "senticol-iii", "name": "SENTICOL III", "nct": "NCT03386734", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry" }, "registry": { "nct": "NCT03386734", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 989, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-05", "completion": "2029-05", "lastUpdate": "2024-07-08" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "swog-s1801", "name": "SWOG S1801", "nct": "NCT03698019", "corpus": { "status": "positive", "phase": "2", "enrolled": 313, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03698019", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 313, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-09-01", "completion": "2026-10-30", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "checkmate-816", "name": "CheckMate 816", "text": "enrolment 358 in the corpus (randomised), 505 on the registry (actual; 29 percent apart): ClinicalTrials.gov lists 505 participants (actual) across all arms, including nivolumab plus ipilimumab; the NEJM 2022 primary analysis compared 179 patients randomised to nivolumab plus chemotherapy with 179 randomised to chemotherapy." }, { "ref": "elective-neck-dissection-tmh", "name": "Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)", "text": "enrolment 596 in the corpus (registered), 710 on the registry (estimated; 16 percent apart): ClinicalTrials.gov lists an estimated 710 participants and the record's status is unknown, meaning the sponsor has not verified it recently; the NEJM 2015 paper reports 596 patients enrolled between 2004 and 2014, with the first 500 analysed." }, { "ref": "emerald-1", "name": "EMERALD-1", "text": "enrolment 616 in the corpus (randomised), 724 on the registry (actual; 15 percent apart): ClinicalTrials.gov lists 724 participants (actual); the Lancet 2025 paper reports 887 patients screened and 616 randomised (204, 207 and 205 across the three arms)." }, { "ref": "niche-2", "name": "NICHE-2", "text": "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." }, { "ref": "sano", "name": "SANO", "text": "enrolment 309 in the corpus (analysed), 776 on the registry (actual; 60 percent apart): ClinicalTrials.gov lists 776 participants (actual); the Lancet Oncology 2025 paper reports 1,115 individuals screened and 309 included in the analysis (198 active surveillance, 111 standard surgery)." } ] }, { "id": "targeted-therapy-roadmap", "name": "Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 27, "checked": 25, "contradictions": 0, "explained": 1, "papers": 3, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "adaura", "name": "ADAURA", "nct": "NCT02511106", "corpus": { "status": "positive", "phase": "3", "enrolled": 682, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02511106", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 682, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-04-11", "completion": "2029-01-31", "lastUpdate": "2026-09-11" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42732874", "doi": "10.1016/j.jtho.2026.104179", "title": "Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175].", "journal": "J Thorac Oncol", "date": "2026-09-13" } ] }, { "id": "alina", "name": "ALINA", "nct": "NCT03456076", "corpus": { "status": "positive", "phase": "3", "enrolled": 257, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT03456076", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 257, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-06-26", "completion": "2031-11-19", "lastUpdate": "2026-07-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "alkove-1", "name": "ALKOVE-1", "nct": "NCT05384626", "corpus": { "status": "positive", "phase": "1/2", "enrolled": 840, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05384626", "status": "RECRUITING", "phases": [ "PHASE1", "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 840, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-01", "lastUpdate": "2026-05-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bruin-cll-321", "name": "BRUIN CLL-321", "nct": "NCT04666038", "corpus": { "status": "positive", "phase": "3", "enrolled": 238, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04666038", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 238, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-29", "completion": "2027-05", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "cadance-304", "name": "CaDAnCe-304", "corpus": { "status": "recruiting", "phase": "3", "enrolledBasis": "registry" }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "codebreak-200", "name": "CodeBreaK 200", "nct": "NCT04303780", "corpus": { "status": "positive", "phase": "3", "enrolled": 345, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT04303780", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 345, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-08-02", "completion": "2026-06-24", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "codebreak-300", "name": "CodeBreaK 300", "nct": "NCT05198934", "corpus": { "status": "positive", "phase": "3", "enrolled": 160, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05198934", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 160, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-07-16", "completion": "2026-04-14", "lastUpdate": "2026-07-22" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "combi-ad", "name": "COMBI-AD", "nct": "NCT01682083", "corpus": { "status": "positive", "phase": "3", "enrolled": 870, "enrolledBasis": "registry", "yearReported": 2017 }, "registry": { "nct": "NCT01682083", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 870, "enrolmentType": "ACTUAL", "primaryCompletion": "2017-06-30", "completion": "2023-07-31", "lastUpdate": "2026-04-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "dreamseq", "name": "DREAMseq (ECOG-ACRIN EA6134)", "nct": "NCT02224781", "corpus": { "status": "positive", "phase": "3", "enrolled": 267, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02224781", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 267, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-09-30", "completion": "2026-12-19", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "flaura2", "name": "FLAURA2", "nct": "NCT04035486", "corpus": { "status": "positive", "phase": "3", "enrolled": 587, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04035486", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 587, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-04-03", "completion": "2027-09-30", "lastUpdate": "2026-09-03" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42728193", "doi": "10.1016/j.lungcan.2026.109588", "title": "Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2.", "journal": "Lung Cancer", "date": "2026-09-14" } ] }, { "id": "gefitinib-chemo-tmh", "name": "Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)", "corpus": { "status": "positive", "phase": "3", "enrolled": 350, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "hera-b31-n9831", "name": "HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)", "nct": "NCT00045032", "corpus": { "status": "positive", "phase": "3", "enrolled": 9000, "enrolledBasis": "registry", "yearReported": 2005 }, "registry": { "nct": "NCT00045032", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 5099, "enrolmentType": "ACTUAL", "primaryCompletion": "2005-03", "completion": "2015-06", "lastUpdate": "2017-04-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "insight-gist", "name": "INSIGHT", "nct": "NCT05734105", "corpus": { "status": "active", "phase": "3", "enrolled": 54, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05734105", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 54, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-12", "completion": "2028-12", "lastUpdate": "2025-12-17" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "krascendo-1", "name": "Krascendo 1", "nct": "NCT06497556", "corpus": { "status": "positive", "phase": "3", "enrolled": 338, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06497556", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 338, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-05-19", "completion": "2029-11-30", "lastUpdate": "2026-09-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "krystal-12", "name": "KRYSTAL-12", "nct": "NCT04685135", "corpus": { "status": "positive", "phase": "3", "enrolled": 453, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT04685135", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 453, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-12-30", "completion": "2026-10-30", "lastUpdate": "2026-08-11" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42745627", "doi": "10.1080/14796694.2026.2719409", "title": "Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS<sup>G12C</sup> mutations.", "journal": "Future Oncol", "date": "2026-09-16" } ] }, { "id": "laura", "name": "LAURA", "nct": "NCT03521154", "corpus": { "status": "positive", "phase": "3", "enrolled": 216, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03521154", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 216, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-01-05", "completion": "2027-10-29", "lastUpdate": "2026-08-04" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "libretto-431", "name": "LIBRETTO-431", "nct": "NCT04194944", "corpus": { "status": "positive", "phase": "3", "enrolled": 261, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04194944", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 261, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-05-01", "completion": "2030-06", "lastUpdate": "2025-10-21" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "litespark-005", "name": "LITESPARK-005", "nct": "NCT04195750", "corpus": { "status": "positive", "phase": "3", "enrolled": 755, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04195750", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 755, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-04-15", "completion": "2026-09-17", "lastUpdate": "2026-05-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "mariposa", "name": "MARIPOSA", "nct": "NCT04487080", "corpus": { "status": "positive", "phase": "3", "enrolled": 1074, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04487080", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1074, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-08-11", "completion": "2028-02-16", "lastUpdate": "2026-08-28" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympia", "name": "OlympiA", "nct": "NCT02032823", "corpus": { "status": "positive", "phase": "3", "enrolled": 1837, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02032823", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1837, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-27", "completion": "2029-05-28", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "profound", "name": "PROfound", "nct": "NCT02987543", "corpus": { "status": "positive", "phase": "3", "enrolled": 387, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02987543", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 387, "enrolmentType": "ACTUAL", "primaryCompletion": "2019-06-04", "completion": "2023-02-15", "lastUpdate": "2023-10-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "rasolute-302", "name": "RASolute 302", "nct": "NCT06625320", "corpus": { "status": "positive", "phase": "3", "enrolled": 500, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06625320", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 500, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-06", "completion": "2027-12", "lastUpdate": "2026-06-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "solo-1", "name": "SOLO-1", "nct": "NCT01844986", "corpus": { "status": "positive", "phase": "3", "enrolled": 391, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo).", "yearReported": 2018 }, "registry": { "nct": "NCT01844986", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 450, "enrolmentType": "ACTUAL", "primaryCompletion": "2018-05-17", "completion": "2028-08-29", "lastUpdate": "2025-12-10" }, "contradictions": [], "explained": [ "enrolment 391 in the corpus (randomised), 450 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo)." ], "papers": [] }, { "id": "telimet-nsclc-01", "name": "TeliMET NSCLC-01", "nct": "NCT04928846", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 768, "enrolledBasis": "registry" }, "registry": { "nct": "NCT04928846", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 768, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-12", "completion": "2029-02", "lastUpdate": "2026-09-16" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "toga", "name": "ToGA", "nct": "NCT01041404", "corpus": { "status": "positive", "phase": "3", "enrolled": 594, "enrolledBasis": "registry", "yearReported": 2010 }, "registry": { "nct": "NCT01041404", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 584, "enrolmentType": "ACTUAL", "primaryCompletion": "2010-06", "completion": "2010-06", "lastUpdate": "2014-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "veritac-2", "name": "VERITAC-2", "nct": "NCT05654623", "corpus": { "status": "mixed", "phase": "3", "enrolled": 624, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05654623", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 624, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-01-31", "completion": "2028-05-15", "lastUpdate": "2026-03-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "solo-1", "name": "SOLO-1", "text": "enrolment 391 in the corpus (randomised), 450 on the registry (actual; 13 percent apart): ClinicalTrials.gov lists 450 participants (actual); the NEJM 2018 primary analysis randomised 391 patients (260 olaparib, 131 placebo)." } ] }, { "id": "tnbc-history", "name": "TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 14, "checked": 14, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent", "name": "ASCENT", "nct": "NCT02574455", "corpus": { "status": "positive", "phase": "3", "enrolled": 529, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02574455", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 529, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-30", "completion": "2020-12-08", "lastUpdate": "2022-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-03", "name": "ASCENT-03", "nct": "NCT05382299", "corpus": { "status": "positive", "phase": "3", "enrolled": 558, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.", "yearReported": 2025 }, "registry": { "nct": "NCT05382299", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 623, "enrolmentType": "ACTUAL", "primaryCompletion": "2028-07", "completion": "2028-07", "lastUpdate": "2026-04-06" }, "contradictions": [], "explained": [ "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." ], "papers": [] }, { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "bl-b01d1-307", "name": "BL-B01D1-307", "nct": "NCT06382142", "corpus": { "status": "positive", "phase": "3", "enrolled": 418, "enrolledBasis": "registry", "yearReported": 2026 }, "registry": { "nct": "NCT06382142", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 418, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-01-13", "completion": "2027-12", "lastUpdate": "2026-07-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "destiny-breast04", "name": "DESTINY-Breast04", "nct": "NCT03734029", "corpus": { "status": "positive", "phase": "3", "enrolled": 557, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03734029", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 557, "enrolmentType": "ACTUAL", "primaryCompletion": "2022-01-11", "completion": "2026-08-01", "lastUpdate": "2025-10-06" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "impassion130", "name": "IMpassion130", "nct": "NCT02425891", "corpus": { "status": "mixed", "phase": "3", "enrolled": 902, "enrolledBasis": "registry", "yearReported": 2018 }, "registry": { "nct": "NCT02425891", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 902, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-04-14", "completion": "2021-08-31", "lastUpdate": "2022-07-19" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "izabright-breast01", "name": "IZABRIGHT-Breast01", "nct": "NCT06926868", "corpus": { "status": "recruiting", "phase": "2/3", "enrolled": 570, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06926868", "status": "RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 600, "enrolmentType": "ESTIMATED", "primaryCompletion": "2028-03-13", "completion": "2030-05-15", "lastUpdate": "2026-08-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-355", "name": "KEYNOTE-355", "nct": "NCT02819518", "corpus": { "status": "positive", "phase": "3", "enrolled": 882, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02819518", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 882, "enrolmentType": "ACTUAL", "primaryCompletion": "2021-06-15", "completion": "2023-10-30", "lastUpdate": "2024-11-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "olympia", "name": "OlympiA", "nct": "NCT02032823", "corpus": { "status": "positive", "phase": "3", "enrolled": 1837, "enrolledBasis": "registry", "yearReported": 2021 }, "registry": { "nct": "NCT02032823", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1837, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-27", "completion": "2029-05-28", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "optimice-pcr", "name": "OptimICE-pCR (A012103)", "nct": "NCT05812807", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 1295, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05812807", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1295, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-05-31", "completion": "2033-05-31", "lastUpdate": "2026-08-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "scarlet-s2212", "name": "SCARLET (SWOG S2212)", "nct": "NCT05929768", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 2400, "enrolledBasis": "registry" }, "registry": { "nct": "NCT05929768", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 2400, "enrolmentType": "ESTIMATED", "primaryCompletion": "2033-03-31", "completion": "2033-04", "lastUpdate": "2025-11-05" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast02", "name": "TROPION-Breast02", "nct": "NCT05374512", "corpus": { "status": "positive", "phase": "3", "enrolled": 644, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05374512", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 644, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-25", "completion": "2026-12-31", "lastUpdate": "2026-05-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast05", "name": "TROPION-Breast05", "nct": "NCT06103864", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 625, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06103864", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 625, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07-28", "completion": "2030-09-30", "lastUpdate": "2026-08-20" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "ascent-03", "name": "ASCENT-03", "text": "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." } ] }, { "id": "trial-modernisation-roadmap", "name": "Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on", "asOf": "2026-09-10", "since": "2026-09-10", "counts": { "trials": 12, "checked": 10, "contradictions": 0, "explained": 1, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "add-aspirin", "name": "Add-Aspirin", "nct": "NCT02804815", "corpus": { "status": "active", "phase": "3", "enrolled": 11000, "enrolledBasis": "registry" }, "registry": { "nct": "NCT02804815", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2026-10", "completion": "2026-10", "lastUpdate": "2025-06-10" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "challenge", "name": "CHALLENGE (CCTG CO.21)", "nct": "NCT00819208", "corpus": { "status": "positive", "phase": "3", "enrolled": 889, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT00819208", "status": "COMPLETED", "phases": [ "NA" ], "studyType": "INTERVENTIONAL", "enrolment": 889, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-02-07", "completion": "2026-03-17", "lastUpdate": "2026-04-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "circulate-japan", "name": "CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)", "corpus": { "status": "active", "phase": "3", "enrolledBasis": "registry", "yearReported": 2023 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "dynamic", "name": "DYNAMIC", "nct": "ACTRN12615000381583", "corpus": { "status": "positive", "phase": "2", "enrolled": 455, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": null, "contradictions": [], "explained": [], "papers": [] }, { "id": "imvigor011", "name": "IMvigor011", "nct": "NCT04660344", "corpus": { "status": "positive", "phase": "3", "enrolled": 761, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04660344", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 761, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-15", "completion": "2026-10-01", "lastUpdate": "2026-03-27" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "keynote-522", "name": "KEYNOTE-522", "nct": "NCT03036488", "corpus": { "status": "positive", "phase": "3", "enrolled": 1174, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT03036488", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 1174, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-10-14", "completion": "2025-10-14", "lastUpdate": "2025-10-29" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "pediatric-match", "name": "NCI-COG Pediatric MATCH (APEC1621)", "nct": "NCT03155620", "corpus": { "status": "active", "phase": "platform", "enrolled": 1377, "enrolledBasis": "registry", "yearReported": 2022 }, "registry": { "nct": "NCT03155620", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 1377, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-03-31", "completion": "2027-01-06", "lastUpdate": "2026-07-24" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "niche-2", "name": "NICHE-2", "nct": "NCT03026140", "corpus": { "status": "positive", "phase": "2", "enrolled": 115, "enrolledBasis": "registered", "enrolledNote": "ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis.", "yearReported": 2022 }, "registry": { "nct": "NCT03026140", "status": "RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 353, "enrolmentType": "ESTIMATED", "primaryCompletion": "2032-03-01", "completion": "2032-03-01", "lastUpdate": "2026-03-05" }, "contradictions": [], "explained": [ "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." ], "papers": [] }, { "id": "persephone", "name": "PERSEPHONE", "nct": "NCT00712140", "corpus": { "status": "positive", "phase": "3", "enrolled": 4088, "enrolledBasis": "registry", "yearReported": 2019 }, "registry": { "nct": "NCT00712140", "status": "UNKNOWN", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 4000, "enrolmentType": "ESTIMATED", "primaryCompletion": "2011-10", "lastUpdate": "2011-09-02" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "phergain", "name": "PHERGain", "nct": "NCT03161353", "corpus": { "status": "positive", "phase": "2", "enrolled": 377, "enrolledBasis": "registry", "yearReported": 2024 }, "registry": { "nct": "NCT03161353", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "enrolment": 377, "enrolmentType": "ACTUAL", "primaryCompletion": "2023-11-01", "completion": "2026-11-01", "lastUpdate": "2025-04-23" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "serena-6", "name": "SERENA-6", "nct": "NCT04964934", "corpus": { "status": "positive", "phase": "3", "enrolled": 315, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT04964934", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 315, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-06-30", "completion": "2028-09-01", "lastUpdate": "2026-07-14" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "stampede", "name": "STAMPEDE", "nct": "NCT00268476", "corpus": { "status": "positive", "phase": "platform", "enrolled": 11992, "enrolledBasis": "registry", "yearReported": 2016 }, "registry": { "nct": "NCT00268476", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE2", "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 11992, "enrolmentType": "ACTUAL", "primaryCompletion": "2026-03", "completion": "2030-12", "lastUpdate": "2023-04-18" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "niche-2", "name": "NICHE-2", "text": "enrolment 115 in the corpus (registered), 353 on the registry (estimated; 67 percent apart): ClinicalTrials.gov lists an estimated 353 participants for the amended NICHE protocol, which is still recruiting to further cohorts; the NEJM 2024 NICHE-2 analysis enrolled 115 patients, 111 of them in the efficacy analysis." } ] }, { "id": "trop2-adc-roadmap", "name": "TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET", "asOf": "2026-09-04", "since": "2026-09-04", "counts": { "trials": 7, "checked": 7, "contradictions": 0, "explained": 1, "papers": 1, "watch": 0, "watchPassed": 0 }, "trials": [ { "id": "ascent", "name": "ASCENT", "nct": "NCT02574455", "corpus": { "status": "positive", "phase": "3", "enrolled": 529, "enrolledBasis": "registry", "yearReported": 2020 }, "registry": { "nct": "NCT02574455", "status": "COMPLETED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 529, "enrolmentType": "ACTUAL", "primaryCompletion": "2020-03-30", "completion": "2020-12-08", "lastUpdate": "2022-06-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "ascent-03", "name": "ASCENT-03", "nct": "NCT05382299", "corpus": { "status": "positive", "phase": "3", "enrolled": 558, "enrolledBasis": "randomised", "enrolledNote": "ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients.", "yearReported": 2025 }, "registry": { "nct": "NCT05382299", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 623, "enrolmentType": "ACTUAL", "primaryCompletion": "2028-07", "completion": "2028-07", "lastUpdate": "2026-04-06" }, "contradictions": [], "explained": [ "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." ], "papers": [] }, { "id": "ascent-04", "name": "ASCENT-04 / KEYNOTE-D19", "nct": "NCT05382286", "corpus": { "status": "positive", "phase": "3", "enrolled": 443, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05382286", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 443, "enrolmentType": "ACTUAL", "primaryCompletion": "2027-02", "completion": "2027-02", "lastUpdate": "2025-09-18" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast01", "name": "TROPION-Breast01", "nct": "NCT05104866", "corpus": { "status": "mixed", "phase": "3", "enrolled": 732, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT05104866", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 732, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-07-24", "completion": "2026-12-31", "lastUpdate": "2026-08-24" }, "contradictions": [], "explained": [], "papers": [ { "pmid": "42727418", "doi": "10.1016/j.esmoop.2026.108538", "title": "Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.", "journal": "ESMO Open", "date": "2026-09-11" } ] }, { "id": "tropion-breast02", "name": "TROPION-Breast02", "nct": "NCT05374512", "corpus": { "status": "positive", "phase": "3", "enrolled": 644, "enrolledBasis": "registry", "yearReported": 2025 }, "registry": { "nct": "NCT05374512", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 644, "enrolmentType": "ACTUAL", "primaryCompletion": "2025-08-25", "completion": "2026-12-31", "lastUpdate": "2026-05-15" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-breast05", "name": "TROPION-Breast05", "nct": "NCT06103864", "corpus": { "status": "recruiting", "phase": "3", "enrolled": 625, "enrolledBasis": "registry" }, "registry": { "nct": "NCT06103864", "status": "RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 625, "enrolmentType": "ESTIMATED", "primaryCompletion": "2027-07-28", "completion": "2030-09-30", "lastUpdate": "2026-08-20" }, "contradictions": [], "explained": [], "papers": [] }, { "id": "tropion-lung01", "name": "TROPION-Lung01", "nct": "NCT04656652", "corpus": { "status": "mixed", "phase": "3", "enrolled": 605, "enrolledBasis": "registry", "yearReported": 2023 }, "registry": { "nct": "NCT04656652", "status": "ACTIVE_NOT_RECRUITING", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "enrolment": 605, "enrolmentType": "ACTUAL", "primaryCompletion": "2024-05-10", "completion": "2027-02-15", "lastUpdate": "2026-08-26" }, "contradictions": [], "explained": [], "papers": [] } ], "watch": [], "contradictions": [], "explained": [ { "ref": "ascent-03", "name": "ASCENT-03", "text": "enrolment 558 in the corpus (randomised), 623 on the registry (actual; 10 percent apart): ClinicalTrials.gov lists 623 participants (actual); the NEJM 2025 primary analysis covered 558 randomised patients." } ] }, { "id": "virtual-cell", "name": "Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell", "asOf": "2026-09-08", "since": "2026-09-08", "counts": { "trials": 0, "checked": 0, "contradictions": 0, "explained": 0, "papers": 0, "watch": 0, "watchPassed": 0 }, "trials": [], "watch": [], "contradictions": [], "explained": [] } ] }